Received Nov 28, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 3 | P2443 | — |
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
Wrong Interval administration; Wrong Interval administration; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too short in a 67-year-old patient who received HAB (Twinrix) (batch number P2443, expiry date 18-SEP-2027) for prophylaxis. Co-suspect products included HAB (Twinrix) for prophylaxis. Concomitant products included HEPATITIS A VACCINE INACT;HEPATITIS B VACCINE RHBSAG (YEAST) (TWINRIX). On 30-AUG-2025, the patient received the 3rd dose of Twinrix. On 08-JUN-2025, the patient received the 2nd dose of Twinrix. On 08-JUN-2025, an unknown time after receiving Twinrix, the patient experienced drug dose administration interval too long (Verbatim: Wrong Interval administration). On 30-AUG-2025, the patient experienced drug dose administration interval too short (Verbatim: Wrong Interval administration). The outcome of the drug dose administration interval too short and drug dose administration interval too long were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 20-NOV-2025 The pharmacist called to get guidance for the Twinrix vaccine series. The patient got 3rd dose before 5 months. The reporter wanted to know if a booster dose was required or if the complete vaccine series had to be restarted. The vaccine administration facility was the same as primary reporter. This case was linked with case US2025150969 and US2025151087 reported by same reporter.; Sender's Comments: US-GSK-US2025150969:Same Reporter US-GSK-US2025151087:Same Reporter